These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32298334)

  • 21. Rationally engineered Cas9 nucleases with improved specificity.
    Slaymaker IM; Gao L; Zetsche B; Scott DA; Yan WX; Zhang F
    Science; 2016 Jan; 351(6268):84-8. PubMed ID: 26628643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genome editing mediated by SpCas9 variants with broad non-canonical PAM compatibility in plants.
    Li J; Xu R; Qin R; Liu X; Kong F; Wei P
    Mol Plant; 2021 Feb; 14(2):352-360. PubMed ID: 33383203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-throughput analysis of the activities of xCas9, SpCas9-NG and SpCas9 at matched and mismatched target sequences in human cells.
    Kim HK; Lee S; Kim Y; Park J; Min S; Choi JW; Huang TP; Yoon S; Liu DR; Kim HH
    Nat Biomed Eng; 2020 Jan; 4(1):111-124. PubMed ID: 31937939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Highly efficient base editing with expanded targeting scope using SpCas9-NG in rabbits.
    Liu Z; Shan H; Chen S; Chen M; Song Y; Lai L; Li Z
    FASEB J; 2020 Jan; 34(1):588-596. PubMed ID: 31914687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.
    Kleinstiver BP; Pattanayak V; Prew MS; Tsai SQ; Nguyen NT; Zheng Z; Joung JK
    Nature; 2016 Jan; 529(7587):490-5. PubMed ID: 26735016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and Analysis of Small Molecule Inhibitors of CRISPR-Cas9 in Human Cells.
    Yang Y; Li D; Wan F; Chen B; Wu G; Li F; Ren Y; Liang P; Wan J; Songyang Z
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An optimized SpCas9 high-fidelity variant for direct protein delivery.
    Pedrazzoli E; Bianchi A; Umbach A; Amistadi S; Brusson M; Frati G; Ciciani M; Badowska KA; Arosio D; Miccio A; Cereseto A; Casini A
    Mol Ther; 2023 Jul; 31(7):2257-2265. PubMed ID: 36905119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crossing enhanced and high fidelity SpCas9 nucleases to optimize specificity and cleavage.
    Kulcsár PI; Tálas A; Huszár K; Ligeti Z; Tóth E; Weinhardt N; Fodor E; Welker E
    Genome Biol; 2017 Oct; 18(1):190. PubMed ID: 28985763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving CRISPR-Cas9 Genome Editing Efficiency by Fusion with Chromatin-Modulating Peptides.
    Ding X; Seebeck T; Feng Y; Jiang Y; Davis GD; Chen F
    CRISPR J; 2019 Feb; 2():51-63. PubMed ID: 31021236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Harnessing the natural diversity and in vitro evolution of Cas9 to expand the genome editing toolbox.
    Karvelis T; Gasiunas G; Siksnys V
    Curr Opin Microbiol; 2017 Jun; 37():88-94. PubMed ID: 28645099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single molecule analysis of effects of non-canonical guide RNAs and specificity-enhancing mutations on Cas9-induced DNA unwinding.
    Okafor IC; Singh D; Wang Y; Jung M; Wang H; Mallon J; Bailey S; Lee JK; Ha T
    Nucleic Acids Res; 2019 Dec; 47(22):11880-11888. PubMed ID: 31713616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A kinetic model predicts SpCas9 activity, improves off-target classification, and reveals the physical basis of targeting fidelity.
    Eslami-Mossallam B; Klein M; Smagt CVD; Sanden KVD; Jones SK; Hawkins JA; Finkelstein IJ; Depken M
    Nat Commun; 2022 Mar; 13(1):1367. PubMed ID: 35292641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induced mutation and epigenetics modification in plants for crop improvement by targeting CRISPR/Cas9 technology.
    Khan MHU; Khan SU; Muhammad A; Hu L; Yang Y; Fan C
    J Cell Physiol; 2018 Jun; 233(6):4578-4594. PubMed ID: 29194606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coupling Cas9 to artificial inhibitory domains enhances CRISPR-Cas9 target specificity.
    Aschenbrenner S; Kallenberger SM; Hoffmann MD; Huck A; Eils R; Niopek D
    Sci Adv; 2020 Feb; 6(6):eaay0187. PubMed ID: 32076642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AcrIIA5 Inhibits a Broad Range of Cas9 Orthologs by Preventing DNA Target Cleavage.
    Song G; Zhang F; Zhang X; Gao X; Zhu X; Fan D; Tian Y
    Cell Rep; 2019 Nov; 29(9):2579-2589.e4. PubMed ID: 31775029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increasing the efficiency of CRISPR-Cas9-VQR precise genome editing in rice.
    Hu X; Meng X; Liu Q; Li J; Wang K
    Plant Biotechnol J; 2018 Jan; 16(1):292-297. PubMed ID: 28605576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Valproic Acid Thermally Destabilizes and Inhibits SpyCas9 Activity.
    Cheng X
    Mol Ther; 2020 Dec; 28(12):2635-2641. PubMed ID: 32882179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Single-Chain Photoswitchable CRISPR-Cas9 Architecture for Light-Inducible Gene Editing and Transcription.
    Zhou XX; Zou X; Chung HK; Gao Y; Liu Y; Qi LS; Lin MZ
    ACS Chem Biol; 2018 Feb; 13(2):443-448. PubMed ID: 28938067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Why Does the E1219V Mutation Expand T-Rich PAM Recognition in Cas9 from
    Bhattacharya S; Satpati P
    J Chem Inf Model; 2024 Apr; 64(8):3237-3247. PubMed ID: 38600752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
    Tadić V; Josipović G; Zoldoš V; Vojta A
    Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.